Twist Bioscience Corporation, a leading provider of high-quality synthetic DNA using its innovative silicon platform, has recently expanded its high-throughput antibody portfolio. The company announced the launch of a CHO (Chinese hamster ovary) cell line for its Twist Express Antibodies, complementing its existing HEK293 expression system. This development aims to address the increasing demand for biotherapeutic drugs manufactured using CHO cell lines, which have become the preferred choice in the biopharmaceutical industry.
CHO Cell Lines as a Preferred Platform for Biotherapeutic Manufacturing
In the field of biopharmaceutical manufacturing, CHO cell lines have gained immense popularity due to their ability to produce complex proteins, including antibodies, with high yield and accuracy. They offer several advantages over other expression systems, such as ease of genetic manipulation, efficient protein folding and post-translational modifications, and proven track record of regulatory approval for biotherapeutic production. As a result, the majority of biotherapeutic drugs on the market today are manufactured using CHO cell lines.
Expansion of Twist Bioscience’s Antibody Portfolio
Recognizing the significance of CHO cell lines in biotherapeutic development, Twist Bioscience has expanded its antibody portfolio by introducing the CHO Express Antibodies. This expansion complements the company’s existing Twist Express Antibodies, which utilize the widely-used HEK293 expression system.
With the addition of CHO Express Antibodies, Twist Bioscience aims to cater to a broader range of projects and customer requirements. The CHO cell line-based antibodies will offer customers a reliable and efficient platform for the development and production of biotherapeutic drugs.
Advantages of Twist Bioscience’s CHO Express Antibodies
Twist Bioscience’s CHO Express Antibodies provide several advantages to researchers and biopharmaceutical companies in their quest for developing novel biotherapeutic drugs. Firstly, the company’s silicon-based DNA synthesis platform ensures the production of high-quality synthetic DNA, enabling faster and more accurate cloning of target antibody genes. This, in turn, facilitates quick cell line engineering and stable protein expression.
Additionally, Twist Bioscience’s expertise in genetic manipulation and cell line optimization allows for the creation and selection of CHO cell lines with optimal productivity and desired characteristics. Through extensive screening and quality control measures, the company ensures the generation of cell lines that exhibit high antibody expression levels, excellent product quality, and consistency.
Implications for the Biopharmaceutical Industry
The launch of Twist Bioscience’s CHO Express Antibodies holds significant implications for the biopharmaceutical industry. The availability of a high-throughput antibody portfolio utilizing CHO cell lines will empower researchers and drug developers to expedite their biotherapeutic discovery and manufacturing processes.
Furthermore, the expansion of Twist Bioscience’s offerings reflects the increasing demand for biotherapeutic drugs and the need for reliable expression systems that ensure the highest quality and consistency. This will foster advancements in the development of innovative antibody-based therapies, ultimately benefiting patients and healthcare providers.
Conclusion:
Twist Bioscience’s expansion of its high-throughput antibody portfolio with the launch of CHO Express Antibodies demonstrates the company’s commitment to meeting the evolving needs of the biopharmaceutical industry. By offering both CHO and HEK293 expression systems, Twist Bioscience provides researchers and drug developers with versatile tools to accelerate and enhance the development and production of biotherapeutic drugs. This advancement signifies a positive step towards advancing the field of biopharmaceuticals and bringing novel therapies to patients in need.
Comments